Pituitary Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Pituitary cancer arising from the
anterior pituitary gland accounts for approximately 15% of intracranial
neoplasms and is typically benign. However, these tumors may metastasize and be
referred to as pituitary carcinoma in rare cases. The underlying etiology of
pituitary gland tumors is not fully understood but likely involves genetic
abnormalities and alterations. Hereditary conditions such as multiple endocrine
neoplasias (MEN)-1 syndrome are associated with an increased risk of pituitary
tumors. The pathophysiology of pituitary cancer is believed to be genetically
related, but specific gene mutations have yet to be fully identified. Pituitary
tumors may be functional, secreting hormones and causing particular symptoms,
or non-functional, without hormone production. The clinical presentation of
pituitary tumors can include symptoms related to the mass effect on surrounding
structures, such as the optic chiasm or cavernous sinus. Surgery is the primary
treatment for pituitary carcinoma and is estimated to have been performed on
80.5% of patients, with some undergoing multiple surgeries. Radiotherapy is
also used in treating pituitary carcinoma, with an estimated 42.9% of patients
receiving at least two courses. Conformal radiotherapy, which aims to provide
both antitumoral and antisecretory effects, can be considered, but data on its
efficacy is limited. Chemotherapy, specifically with the oral alkylating agent
temozolomide, is also used in treating pituitary carcinoma and has improved
progression-free and overall survival rates. Antisecretory medications, such as
dopamine agonists, steroidogenesis inhibitors, and somatostatin analogues, are
also crucial in controlling pituitary hormone hypersecretion in patients with
pituitary carcinoma.
·
The incidence of Pituitary cancer ranges from
3.9 to 7.4 cases per 100,000 population in the USA.
Thelansis’s “Pituitary Cancer Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Pituitary
Cancer treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Pituitary Cancer across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Pituitary Cancer Market Forecast Patient-Based
Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with
sourcing, Market Event, and Product Event, Country specific Forecast Model,
Market uptake and patient share uptake, Attribute Analysis, Analog Analysis,
Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment